On August 1, 2025, Amneal Pharmaceuticals borrowed $2.1 billion through a new term loan and issued $600 million in senior secured notes to refinance existing debts and improve financial flexibility. These financial moves are crucial for the company's future operations, reflecting significant changes in its capital structure.